PMID- 25410225
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20141121
IS  - 0072-9752 (Print)
IS  - 0072-9752 (Linking)
VI  - 126
DP  - 2014
TI  - Sexual dysfunction in diabetes.
PG  - 223-32
LID - B978-0-444-53480-4.00017-5 [pii]
LID - 10.1016/B978-0-444-53480-4.00017-5 [doi]
AB  - We aimed to summarize the etiology, clinical characteristics, diagnosis, and 
      possible treatment options of sexual dysfunction in diabetic patients of both 
      sexes. Details of dysfunction in diabetic women are less conclusive than in men 
      due to the lack of standardized evaluation of sexual function in women. Male 
      sexual dysfunction is a common complication of diabetes, including abnormalities 
      of orgasmic/ejaculatory function and desire/libido in addition to penile 
      erection. The prevalence of erectile dysfunction (ED) among diabetic men varies 
      from 35% to 75%. Diabetes-induced ED has a multifactorial etiology including 
      metabolic, neurologic, vascular, hormonal, and psychological components. ED 
      should be regarded as the first sign of cardiovascular disease because it can be 
      present before development of symptomatic coronary artery disease, as larger 
      coronary vessels better tolerate the same amount of plaque compared to smaller 
      penile arteries. The diagnosis of ED is based on validated questionnaires and 
      determination of functional and organic abnormalities. First-, second- and 
      third-line therapy may be applied. Phosphodiesterase-5 (PDE-5) inhibitor 
      treatment from the first-line options leads to smooth muscle relaxation in the 
      corpus cavernosum and enhancement in blood flow, resulting in erection during 
      sexual stimulus. The use of PDE-5 inhibitors in the presence of oral nitrates is 
      strictly contraindicated in diabetic men, as in nondiabetic subjects. All PDE-5 
      inhibitors have been evaluated for ED in diabetic patients with convincing 
      efficacy data. Second-line therapy includes intracavernosal, trans- or 
      intraurethral administration of vasoactive drugs or application of a vacuum 
      device. Third-line therapies are the implantation of penile prosthesis and penile 
      revascularization.
FAU - Tamas, Varkonyi
AU  - Tamas V
AD  - First Department of Internal Medicine, University of Szeged, Szeged, Hungary. 
      Electronic address: varkonyitamas@gmail.com.
FAU - Kempler, Peter
AU  - Kempler P
AD  - First Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Handb Clin Neurol
JT  - Handbook of clinical neurology
JID - 0166161
RN  - 0 (Phosphodiesterase 5 Inhibitors)
SB  - IM
MH  - Animals
MH  - Clinical Trials as Topic/methods
MH  - Diabetes Mellitus/*diagnosis/*epidemiology/therapy
MH  - Erectile Dysfunction/diagnosis/epidemiology/therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Phosphodiesterase 5 Inhibitors/pharmacology/therapeutic use
MH  - Sexual Behavior/drug effects/physiology
MH  - Sexual Dysfunction, Physiological/*diagnosis/*epidemiology/therapy
OTO - NOTNLM
OT  - Princeton guidelines
OT  - Sexual dysfunction
OT  - artery size hypothesis
OT  - erectile dysfunction
OT  - phosphodiesterase-5 inhibitors
EDAT- 2014/11/21 06:00
MHDA- 2016/07/29 06:00
CRDT- 2014/11/21 06:00
PHST- 2014/11/21 06:00 [entrez]
PHST- 2014/11/21 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
AID - B978-0-444-53480-4.00017-5 [pii]
AID - 10.1016/B978-0-444-53480-4.00017-5 [doi]
PST - ppublish
SO  - Handb Clin Neurol. 2014;126:223-32. doi: 10.1016/B978-0-444-53480-4.00017-5.